Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP026
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
AP026 is a recombinant fusion protein being developed by Chia Tai Tianqing Pharmaceutical Group and Sino Biopharmaceutical. It is designed to modulate fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 (GLP-1) pathways. The drug is currently in Phase I clinical trials for the treatment of type 2 diabetes mellitus and non-alcoholic steatohepatitis.
02
Targets
FGF21 (Fibroblast growth factor 21)GLP1R (GLP-1R)
Beyond the preview
Go deeper on AP026.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP026.